Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer - PubMed (original) (raw)
Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer
Carmen Blanco-Aparicio et al. Carcinogenesis. 2007 Mar.
Abstract
AKT1/PKB is a serine/threonine protein kinase that regulates biological processes such as proliferation, apoptosis and growth in a variety of cell types. To assess the oncogenic capability of an activated form of AKT in vivo we have generated several transgenic mouse lines that overexpress in the mammary epithelium the murine Akt1 gene modified with a myristoylation signal, which renders active this protein by localizing it to the plasma membrane. We demonstrate that expression of myristoylated AKT in the mammary glands increases the susceptibility of these mice to the induction of mammary tumors of epithelial origin by the carcinogen 9,10-dimethyl-1,2 benzanthracene (DMBA). We have found that while carcinogen-treated wild-type mice show mostly mammary tumors of sarcomatous origin, AKT transgenic mice treated with DMBA developed mainly adenocarcinoma or adenosquamous tumors, all of them displaying activated AKT. We analyzed other possible molecular alterations cooperating with AKT and found that neither Ras nor beta-catenin/Wnt pathways seemed altered nor p53 mutated. We have found that 100% of mammary DMBA-induced tumors and benign lesions in myrAKT mice are estrogen receptor (ERalpha)-positive and are more frequent than in wild-type littermates. These data show that AKT activation cooperates with deregulation of the estrogen receptor in the DMBA-induced mammary tumorigenesis model and recapitulate two characteristics of some human breast tumors. Thus, our model might provide a preclinical relevant model system to study the role of AKT and ERalpha in breast tumorigenesis and the response of mammary gland tumors to chemotherapeutics.
Similar articles
- Activation of Akt1 accelerates carcinogen-induced tumorigenesis in mammary gland of virgin and post-lactating transgenic mice.
Wu Y, Kim J, Elshimali Y, Sarkissyan M, Vadgama JV. Wu Y, et al. BMC Cancer. 2014 Apr 17;14:266. doi: 10.1186/1471-2407-14-266. BMC Cancer. 2014. PMID: 24742286 Free PMC article. - Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis.
Kuang SQ, Liao L, Wang S, Medina D, O'Malley BW, Xu J. Kuang SQ, et al. Cancer Res. 2005 Sep 1;65(17):7993-8002. doi: 10.1158/0008-5472.CAN-05-1179. Cancer Res. 2005. PMID: 16140972 - An expression study of hormone receptors in spontaneously developed, carcinogen-induced and hormone-induced mammary tumors in female Noble rats.
Cheung SY, Yuen MT, Choi HL, Cheng HK, Huang Y, Chen S, Chan FL. Cheung SY, et al. Int J Oncol. 2003 Jun;22(6):1383-95. Int J Oncol. 2003. PMID: 12739009 - Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis.
Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, Korach KS, Devanesan P, Todorovic R, Rogan EG, Cavalieri EL. Yue W, et al. J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):477-86. doi: 10.1016/s0960-0760(03)00377-7. J Steroid Biochem Mol Biol. 2003. PMID: 14623547 Review. - Induced mammary cancer in rat models: pathogenesis, genetics, and relevance to female breast cancer.
Miller JL, Bartlett AP, Harman RM, Majhi PD, Jerry DJ, Van de Walle GR. Miller JL, et al. J Mammary Gland Biol Neoplasia. 2022 Jun;27(2):185-210. doi: 10.1007/s10911-022-09522-w. Epub 2022 Jul 29. J Mammary Gland Biol Neoplasia. 2022. PMID: 35904679 Review.
Cited by
- Tip30 deletion in MMTV-Neu mice leads to enhanced EGFR signaling and development of estrogen receptor-positive and progesterone receptor-negative mammary tumors.
Zhang C, Mori M, Gao S, Li A, Hoshino I, Aupperlee MD, Haslam SZ, Xiao H. Zhang C, et al. Cancer Res. 2010 Dec 15;70(24):10224-33. doi: 10.1158/0008-5472.CAN-10-3057. Cancer Res. 2010. PMID: 21159643 Free PMC article. - Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications.
Badve S, Collins NR, Bhat-Nakshatri P, Turbin D, Leung S, Thorat M, Dunn SE, Geistlinger TR, Carroll JS, Brown M, Bose S, Teitell MA, Nakshatri H. Badve S, et al. Am J Pathol. 2010 May;176(5):2139-49. doi: 10.2353/ajpath.2010.090477. Epub 2010 Mar 12. Am J Pathol. 2010. PMID: 20228224 Free PMC article. - Genetic modelling of the PTEN/AKT pathway in cancer research.
Renner O, Blanco-Aparicio C, Carnero A. Renner O, et al. Clin Transl Oncol. 2008 Oct;10(10):618-27. doi: 10.1007/s12094-008-0262-1. Clin Transl Oncol. 2008. PMID: 18940742 Review. - Activation of Akt1 accelerates carcinogen-induced tumorigenesis in mammary gland of virgin and post-lactating transgenic mice.
Wu Y, Kim J, Elshimali Y, Sarkissyan M, Vadgama JV. Wu Y, et al. BMC Cancer. 2014 Apr 17;14:266. doi: 10.1186/1471-2407-14-266. BMC Cancer. 2014. PMID: 24742286 Free PMC article. - Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis.
Mancini ML, Lien EC, Toker A. Mancini ML, et al. Oncotarget. 2016 Apr 5;7(14):17301-13. doi: 10.18632/oncotarget.8191. Oncotarget. 2016. PMID: 27004402 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous